Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 612-618

  Ocheni, Sunday ^a,b   Zabelina, Tatjana ^a   Bacher, Ulrike ^a   Ayuk, Francis ^a   Zander, Axel ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b University of Nigeria Enugu Campus ^*  (Nigeria)

Author keywords

Allogeneic stem cell transplantation; Granulocyte stimulating factor; Pegylated granulocyte stimulating factor; Peripheral blood stem cells; Unrelated donors

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; ITRACONAZOLE; MELPHALAN; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; TREOSULFAN; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NEUTROPHIL COUNT; ORGAN DONOR; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; THALASSEMIA; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; BLOOD DONORS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68449091364     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902777442     Document Type: Article

References (38)

1. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006;24: 5207-5215.
2. Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA, Li W, Buckner CD, et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997;19:671-678.
3. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-411.
4. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial. J Clin Oncol 1995;13:1323-1327.
5. Hornedo J, Sola C, Solano C, Lopez JJ, Alonso S, Lluch A, et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002;29:737-743.
6. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661-670.
7. Dunn CJ, Goa KL. Lenograstim: An update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000;59:681-717.
8. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: Results of a double-blind, randomized trial. Bone Marrow Transplant 2004;34:955-962.
9. Suh C, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, et al. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: A prospective randomized evaluation of two different fixed doses. Transfusion 2004;44:533-538.
10. Urbano-Ispizua A, Solano C, Brunet S, Hernandez F, Sanz G, Alegre A, et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group. Bone Marrow Transplant 1996;18:35-40.
11. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006;34:382-388.
12. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
13. Molineux G. Pegfilgrastim: Using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003;14:259-264.
14. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-1734.
15. Morstyn G, Foote MA, Walker T, Molineux G. Filgrastim (rmetHuG- CSF) in the 21st century: SD/01. Acta Haematol 2001;105:151-155.
16. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001;7:2085-2090.
17. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-519.
18. Cheung E, Cozenza, M, Lopez O. Modeling of r-metHUGCSF- SD/01 mediated granulopoiesis in normal animals, with mathematical extrapolation to neutropenic settings. Blood 1998;92:379a. ASH annual meeting abstracts.
19. Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 2003;32:399-404.
20. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: Clinical benefits at no extra cost. Br J Cancer 1998;77:1294-1299.
21. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005;35:889-893.
22. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study. Bone Marrow Transplant 2005;35:1165-1169.
23. Lyman GH. Pegfilgrastim: A granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005;5:1635-1646.
24. De la Rubia J. Pegfilgrastim as adjunct to chemotherapy to mobilize hematopoietic stem cells. Haematologica 2005; 90:150.
25. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007;39:743-750.
26. + peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin- containing regimens. Bone Marrow Transplant 2006;38:413-416.
27. Malerba L, Mele A, Leopardi G, Stramigioli S, Politi P, Visani G. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Eur J Haematol 2006;76: 436-439.
28. + progenitors in patients with multiple myeloma. Transfusion 2006;46:180-185.
29. + peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-1671.
30. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after highdose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006;34:1296-1302.
31. Kroschinsky F, Holig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-1423.
32. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-36.
33. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
34. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
35. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
36. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 88:1907-1929.
37. Martino M, Pratico G, Messina G, Irrera G, Massara G, Console G, Iacopino. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77:410-415.
38. Musto P, Scalzulli PR, Terruzzi E, Rossini F, Iacopino P, Messina G, et al. Peg-filgrastim versus filgrastim aftzer autologous stem cell transplantation: Case control study in patients with multiple myeloma and review of the literature. Leuk Res 2007;31:1487-1493.